A phase II study of pacritinib in patients with myelofibrosis demonstrated that pacritinib is active in patients with myelofibrosis, resulting in spleen volume reduction, while producing substantial and prolonged improvement in disease-related symptoms without causing clinically significant myelosuppression.
When The Cancer Letter founder Jerry Boyd carried the first print run of his little eight page oncology newsletter into an NCAB meeting in 1973, he certainly could not have predicted that, half a century later, his experiment would branch out into this thing called “podcasts.”
